Sargent Investment Group, LLC Cytosorbents Corp Transaction History

Sargent Investment Group, LLC

  • $702 Million
  • Q2 2025

A detailed history of Sargent Investment Group, LLC transactions in Cytosorbents Corp stock. As of the latest transaction made, Sargent Investment Group, LLC holds 746,200 shares of CTSO stock, worth $790,972. This represents 0.14% of its overall portfolio holdings.

Number of Shares
746,200
Previous 823,500 9.39%
Holding current value
$790,972
Previous $823,000 16.04%
% of portfolio
0.14%
Previous 0.13%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
SELL
$0.81 - $1.28 $62,613 - $98,944
-77,300 Reduced 9.39%
746,200 $955,000
Q1 2025

May 05, 2025
SELL
$0.89 - $1.3 $378,573 - $552,971
-425,363 Reduced 34.06%
823,500 $823,000
Q4 2024

Jan 27, 2025
SELL
$0.74 - $1.35 $279,264 - $509,468
-377,384 Reduced 23.21%
1,248,863 $1.12 Million
Q3 2024

Nov 06, 2024
BUY
$0.7 - $1.55 $134,922 - $298,757
192,747 Added 13.45%
1,626,247 $2.44 Million
Q2 2024

Aug 09, 2024
BUY
$0.7 - $1.01 $47,026 - $67,852
67,181 Added 4.92%
1,433,500 $1 Million
Q1 2024

May 10, 2024
BUY
$0.86 - $1.07 $49,511 - $61,602
57,572 Added 4.4%
1,366,319 $1.3 Million
Q4 2023

Feb 05, 2024
BUY
$1.08 - $1.94 $55,834 - $100,296
51,699 Added 4.11%
1,308,747 $1.45 Million
Q3 2023

Nov 13, 2023
SELL
$1.86 - $4.03 $60,446 - $130,966
-32,498 Reduced 2.52%
1,257,048 $2.36 Million
Q2 2023

Jul 31, 2023
BUY
$2.37 - $3.65 $168,300 - $259,197
71,013 Added 5.83%
1,289,546 $4.63 Million
Q1 2023

May 02, 2023
BUY
$1.79 - $4.17 $419,576 - $977,448
234,400 Added 23.82%
1,218,533 $4.11 Million
Q4 2022

Jan 31, 2023
SELL
$1.03 - $2.03 $127,823 - $251,922
-124,100 Reduced 11.2%
984,133 $1.53 Million
Q3 2022

Oct 26, 2022
BUY
$1.2 - $2.46 $156,884 - $321,613
130,737 Added 13.37%
1,108,233 $2.03 Million
Q2 2022

Jul 26, 2022
BUY
$1.76 - $3.22 $264,204 - $483,373
150,116 Added 18.14%
977,496 $2.14 Million
Q1 2022

May 06, 2022
BUY
$2.88 - $4.23 $122,526 - $179,961
42,544 Added 5.42%
827,380 $2.64 Million
Q4 2021

Feb 11, 2022
SELL
$4.05 - $8.11 $726,185 - $1.45 Million
-179,305 Reduced 18.6%
784,836 $3.29 Million
Q3 2021

Nov 12, 2021
BUY
$7.0 - $9.71 $754,782 - $1.05 Million
107,826 Added 12.59%
964,141 $7.83 Million
Q2 2021

Aug 05, 2021
BUY
$7.55 - $9.42 $544,694 - $679,605
72,145 Added 9.2%
856,315 $6.47 Million
Q1 2021

May 04, 2021
BUY
$8.23 - $11.48 $910,114 - $1.27 Million
110,585 Added 16.42%
784,170 $6.81 Million
Q4 2020

Feb 10, 2021
SELL
$7.65 - $8.98 $146,520 - $171,993
-19,153 Reduced 2.76%
673,585 $5.37 Million
Q3 2020

Nov 12, 2020
SELL
$7.37 - $11.54 $52,083 - $81,553
-7,067 Reduced 1.01%
692,738 $5.52 Million
Q2 2020

Aug 11, 2020
BUY
$6.28 - $10.59 $1.43 Million - $2.42 Million
228,050 Added 48.34%
699,805 $6.98 Million
Q1 2020

May 12, 2020
BUY
$3.77 - $7.73 $771,907 - $1.58 Million
204,750 Added 76.68%
471,755 $3.65 Million
Q4 2019

Feb 11, 2020
BUY
$3.61 - $5.22 $126,350 - $182,700
35,000 Added 15.09%
267,005 $1.03 Million
Q4 2019

Jan 30, 2020
SELL
$3.61 - $5.22 $230,715 - $333,610
-63,910 Reduced 21.6%
232,005 $893,000
Q3 2019

Oct 29, 2019
SELL
$4.33 - $7.63 $164,518 - $289,901
-37,995 Reduced 11.38%
295,915 $1.49 Million
Q2 2019

Aug 12, 2019
BUY
$5.92 - $7.78 $271,372 - $356,635
45,840 Added 15.91%
333,910 $2.21 Million
Q1 2019

May 13, 2019
BUY
$6.82 - $8.56 $263,524 - $330,758
38,640 Added 15.49%
288,070 $2.18 Million
Q4 2018

Feb 12, 2019
BUY
$7.05 - $12.64 $1.76 Million - $3.15 Million
249,430 New
249,430 $2.02 Million

Others Institutions Holding CTSO

# of Institutions
52
Shares Held
16.7M
Call Options Held
28.9K
Put Options Held
0
View Full List

About Cytosorbents Corp

CTSO Quotes by TradingView
  • Ticker CTSO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 43,577,400
  • Market Cap $46.2M
  • Description
  • Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...
More about CTSO
Track This Portfolio

Track Sargent Investment Group, LLC Portfolio

Follow Sargent Investment Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Investment Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Investment Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email